World Money Crisis Causes India’s Piramal To Delay Raising Funds
This article was originally published in PharmAsia News
Executive Summary
India's Piramal Life Sciences says it has to put off launching a strategic stake sale as a way to raise funds, citing the global financial crisis. PLSL used to be the research and development arm of Piramal Healthcare until it was split off. Swati Piramal, director of the Piramal Group, said PLSL does not need immediate funds to continue operating, so it will defer its fund-raising plans until the world financial situation improves. (Click here for more
You may also be interested in...
Piramal’s Buyout Of Minrad May Dent Strongholds Of Abbott, Baxter
MUMBAI - Abbott and Baxter are set to face strong competition in their traditional businesses of hospital anesthetic gas products as India's Piramal Healthcare has announced its acquisition of U.S. based Minrad International, a provider of generic inhalation anesthetics that include isoflurane, enflurane and sevoflurane. In addition, Minrad has filed an abbreviated new drug application for desflurane with U.S. FDA
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.